Bioventus financials
$14.00−0.14%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $568.1M | $573.3M | $512.3M | $512.1M | $430.9M |
| Gross profit | $388.2M | $388.2M | $328.2M | $331.1M | $302.7M |
| Gross margin | 68.3% | 67.7% | 64.1% | 64.6% | 70.3% |
| Operating income | $54.1M | $21.5M | $467.0K | -$42.5M | $12.1M |
| Net income | $22.7M | -$36.1M | -$156.2M | -$158.7M | -$6.6M |
| Net margin | 4.0% | −6.3% | −30.5% | −31.0% | −1.5% |
| Diluted EPS | $0.33 | $-0.56 | $-2.49 | $-2.59 | $-0.15 |
| EBITDA | $103.3M | $71.0M | $58.7M | $20.7M | $55.9M |
| Operating cash flow | $74.7M | $38.8M | $15.3M | -$13.5M | $22.2M |
| Free cash flow | $72.1M | $37.8M | $8.0M | -$15.0M | $8.6M |
| Diluted shares | 68.9M | 64.5M | 62.6M | 61.4M | 45.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $51.2M | $41.6M | $37.0M | $30.2M | $43.9M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Total debt | $294.0M | $335.6M | $394.8M | $418.1M | $357.7M |
| Total assets | $683.6M | $728.0M | $810.9M | $1.37B | $1.23B |
| Total liabilities | $455.1M | $542.4M | $589.8M | $960.4M | $692.1M |
| Shareholders' equity | $228.4M | $185.6M | $221.1M | $412.2M | $533.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology